- Open
- 0.20
- High
- 0.20
- Low
- 0.18
- Close
- 0.18
- Change
- -0.03 (-17.07%)
- Volume
- 7,318,513
⌘K
| 28 May 2026 | 07:00:03 | Half Year Report |
| 31 Mar 2026 | 07:00:01 | Total Voting Rights |
| 11 Mar 2026 | 07:00:07 | £1.0 million Placing |
| 10 Mar 2026 | 07:00:11 | Confirmation of US ODD for NXP002 in IPF |
Nuformix is a company that focuses on pharmaceutical development and the discovery of new drug forms. They are dedicated to addressing unmet medical needs in the areas of fibrosis and oncology through drug repurposing.
| 28 May 2026 | 07:00:03 | Half Year Report |
| 31 Mar 2026 | 07:00:01 | Total Voting Rights |
| 11 Mar 2026 | 07:00:07 | £1.0 million Placing |
| 10 Mar 2026 | 07:00:11 | Confirmation of US ODD for NXP002 in IPF |
Nuformix is a company that focuses on pharmaceutical development and the discovery of new drug forms. They are dedicated to addressing unmet medical needs in the areas of fibrosis and oncology through drug repurposing.
| 3 Mar 2026 |
| 10:05:00 |
| Result of AGM |
| 3 Mar 2026 |
| 10:05:00 |
| Result of AGM |
